Compound 88 was found to suppress HUVEC (human umbilical vein endothelial cell) proliferation caused by VEGF, bFGF (basic fibroblast growth factor), or ECGS (endothelial cell growth supplement) (IC50s: 1.4, 2.8 μM, and 6.2 μM, respectively) compared to SU5416 (a tyrosine kinase inhibitor, IC50s: 0.05, 5.3, and 30.5 μM, respectively) [34] and demonstrated selective cytotoxic capacity versus A549 (human lung adenocarcinoma epithelial cell line) (IC50 < 10 μM) [55]. This evidence concerns the gene FGF2 and lung adenocarcinoma.